T-cells activated with a trifunctional bispecific antibody in head and neck cancer;Removab® aktivierte lymphozyten bei plattenepithelkarzinomen des oberen aerodigestivtraktes

Laryngo- Rhino- Otologie

Volumn 84, Issue 11, 2005, Pages 822-828

  Gronau, Silke ^a   Schmitt, M ^a   Reinhardt, P ^a   Wiesneth, M ^a   Riechelman, S ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Bispecific antibodies; Chorioallantois membrane; Head and neck squamous cell carcinoma; Immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; CISPLATIN; CYTOKINE; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; REMOVAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; IMMUNOGLOBULIN RECEPTOR; IMMUNOLOGIC FACTOR; OPSONIN RECEPTOR; TACSTD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL VIABILITY; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; OPSONIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEPSIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; ADULT; AGED; ANIMAL; BLOOD; CELL CULTURE; CELL SURVIVAL; CHICK EMBRYO; CYTOTOXICITY TEST; DRUG EFFECT; FEMALE; HEAD AND NECK TUMOR; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEUTROPHIL; T LYMPHOCYTE;

ADULT; AGED; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL SURVIVAL; CHICK EMBRYO; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEUTROPHILS; OTORHINOLARYNGOLOGIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SKIN WINDOW TECHNIQUE; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 28744439245     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-861448     Document Type: Article

References (25)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36
2. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002; 14: 334-342
3. Hoff PM, Ellis LM, Abbruzzese JL. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? Oncology (Huntingt) 2004; 18: 736-741
4. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer 2004. Am. J Clin Pathol 2004; 122 (4): 598-609
5. Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Bare) 2003; 39(Suppl C): 61-80
6. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526-2534
7. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163: 1246-1252
8. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83: 261-266
9. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155: 219-225
10. Lindhofer H, Menzel H, Gunther W, Hultner L, Thierfelder S. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 1996; 88: 4651-4658
11. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001; 49: 911-917
12. Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A. TNFα contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 2001; 21: 3499-3503
13. Wollenberg B, Ledderose H, Pauli M, Andratschke M, Lebeau A, Lindhofer H, Kastenbauer E, Zeidler R. Pilotstudie mit bispezifischen Antikörpern bei Patienten mit Plattenepithelkarzinomen des Kopf-Hals-Bereiches. HNO 1999; 47: 439
14. Hirota J, Ueta E, Osaki T, Ogawa Y. Immunohistologic study of mononuclear cell infiltrates in oral squamous cell carcinomas. Head Neck 1990; 12: 118-125
15. Lang S, Atarashi Y, Nishioka Y, Stanson J, Meidenbauer N, Whiteside TL. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cell Immunol 2000; 201: 132-143
16. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S. Opsonization with a trifunctional bispecific (αCD3 × alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004; 25: 841-848
17. Gual A, Eugenin J, Alcayaga J, Stensaas LJ, Eyzaguirre C. The chick chorioallantoic membrane promotes survival of co-transplanted rat carotid bodies and nodose ganglia. Brain Res 1991; 556: 139-144
18. Owen JJ, Harrison GA. Studies on human leucocytes in diffusion chambers on the chick chorioallantois. Transplantation 1967; 5: 643-651
19. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968; 97: 77
20. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279
21. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004; 10: 2584-2586
22. !2 Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004; 40: 1292-1301
23. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002; 51: 389-396
24. Takes RP, Baatenburg De Jong RJ, Keuning J, Hermans J, Schuuring E, Van Krieken HJ. Protein expression of cancer associated genes: biopsy material compared to resection material in laryngeal cancer. Anticancer Res 1998; 18: 4787-4791
25. Takes RP, Baatenburg De Jong RJ, Alles MJ, Meeuwis CA, Marres HA, Knegt PP, De La Riviere GB, De Wilde PC, Mooi WJ, Hermans J, Van Krieken JH, Keuning J, Schuuring E, Van Krieken HJ. Markers for nodal metastasis in head and neck squamous cell cancer Protein expression of cancer associated genes: biopsy material compared to resection material in laryngeal cancer. Arch Otolaryngol Head Neck Surg 2002; 128: 512-518